Work

A Phase I Trial of 90 Y-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients with Metastatic CEA-Producing Malignancies

Year: 2006

Type: article

Study design: Clinical Trial

Source: Cancer Biotherapy and Radiopharmaceuticals

DOI: 10.1089/cbr.2006.21.88

Authors: Jeffrey Y.C. Wong, David Z. Chu, Lawrence E. Williams, An Liu, Jiping Zhan, Dave M. Yamauchi, Sharon Wilczynski, Anna M. Wu, Paul J. Yazaki, John E. Shively, Lucille Leong, Andrew A. Raubitschek

Institutions: City Of Hope National Medical Center, Beckman Research Institute, University of California, Los Angeles

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: U.S. Food and Drug Administration, U.S. Public Health Service

Awards: G5810891794, G6376908427

OpenAlex ID: W2090222871

FWCI: 2.015

Cites: 53

Cited by: 51

Related to: 10